
Please try another search
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Andrew C. Dreyfus | 63 | 2016 | Independent Director |
Michael E. Mendelsohn | 67 | 2017 | Member of Pharmaceutical Advisory Committee |
Catherine Moukheibir | 63 | 2019 | Independent Director |
Jon R. Duane | 64 | 2019 | Independent Director |
Perry V. Halushka | - | - | Member of Pharmaceuticals Advisory Committee |
Marla L. Kessler | 53 | 2019 | Independent Director |
Alexander John Denner | 54 | 2020 | Independent Director |
Mark G. Currie | 69 | 2002 | Independent Director |
Julie H. McHugh | 60 | 2014 | Independent Chairman of the Board |
Jay P. Shepard | 66 | 2020 | Independent Director |
Thomas A. McCourt | 68 | 2009 | CEO & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review